Evotec SE (EVO) Stock
1 of the hedge funds AlphaScala tracks reported EVO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $63.9K.
Which hedge funds own EVO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 23K | $63.9K | -77% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →EVO price chart
Powered by TradingViewWhat does Evotec SE do?
Evotec SE Sponsored ADR represents shares in Evotec SE, a leading biotechnology company headquartered in Germany. Renowned for its innovative approach, Evotec SE specializes in drug discovery and development across several therapeutic areas, including neuroscience, oncology, and infectious diseases. The company leverages advanced technologies and data-driven solutions to accelerate the drug discovery process, aiming to provide novel content, platforms, and capabilities to its partners in the pharmaceutical and biotechnology sectors. As a Sponsored American Depository Receipt (ADR), it allows U.S. investors to gain exposure to Evotec SE without the complexities of investing directly in foreign stocks. This ADR facilitates access through platforms and brokerages familiar to U.S. traders, thus playing a crucial role in increasing the company's investor base outside Europe. In the global finance market, Evotec SE is recognized for its commitment to transforming the scientific innovation landscape by fostering strategic collaborations and investing in disruptive technologies.